This article is more than 5 years old. Information may no longer be current.

ThromboGenics initiates phase 2b trial of microplasmin in vitrectomy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LEUVEN, Belgium — ThromboGenics NV has initiated a phase 2b randomized, controlled U.S. clinical trial of microplasmin in vitrectomy, the company announced.

Microplasmin, a truncated form of the natural human protein plasmin, is being developed as a means to facilitate the induction of posterior vitreous detachment, according to the company. Injected before vitrectomy, the drug is intended to speed surgery and reduce complications.

The phase 2b study, dubbed Microplasmin for Vitreous Injection III, will evaluate the safety and efficacy of the drug in 120 patients at 12 centers. Company officials expect the results to allow dose selection for subsequent phase 3 studies, according to a press release from ThromboGenics.

The company has also begun patient enrollment in a phase 2 study in Europe evaluating microplasmin for treatment of diabetic macular edema and other retinal conditions, the release said.